7,81 $
6,11 % gestern
Nasdaq, 6. Oktober, 22:00 Uhr
ISIN
US14070B1017
Symbol
CAPR
Berichte

Capricor Therapeutics, Inc. Aktie News

Neutral
GlobeNewsWire
4 Tage alt
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.
Positiv
Seeking Alpha
7 Tage alt
Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non-ambulatory DMD patients, offering a unique mechanism and favorable safety profile compared to gene therapies like Elevidys. Strong regulatory designations, strategic partnerships, and a robust cas...
Positiv
Seeking Alpha
8 Tage alt
Based on prior, preclinical and clinical data, including 2 small randomized trials, I believe there is a high probability that Capricor Therapeutics' phase 3 trial will be positive. Topline results are expected this November. PUL 2.0 (a skeletal muscle endpoint) remains the primary endpoint, with left ventricle ejection fraction being a key secondary endpoint. Regulatory uncertainty remains on ...
Neutral
Seeking Alpha
12 Tage alt
Capricor Therapeutics, Inc. - Special Call Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Madison Wynne El-Saadi - B.
Neutral
GlobeNewsWire
12 Tage alt
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for its Biologics License Application (BLA) for Deramiocel, the Company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). This update f...
Neutral
GlobeNewsWire
14 Tage alt
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.
Neutral
GlobeNewsWire
20 Tage alt
Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Capricor between October 9, 2024 and July 10, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 35...
Neutral
PRNewsWire
21 Tage alt
NEW YORK , Sept. 15, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"), of the important September 15, 2025 lead plaintiff deadline.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen